STIMULUS MDS-US : Sabatolimab Added to HMA in Higher Risk MDS
Status:
Not yet recruiting
Trial end date:
2025-04-30
Target enrollment:
Participant gender:
Summary
Main objective of this study is to describe and evaluate safety and efficacy of MBG453
(sabatolimab) in combination with FDA approved HMAs of investigator's choice (IV Decitabine
or Azacitidine /SC Azacitidine /Oral Decitabine (cedazuridine combination (INQOVI))